The FDA on Thursday approved Fabhalta (iptacopan) to treat complement 3 glomerulopathy (CG3), a progressive, ultrarare kidney ...

Kepler Capital analyst David Evans maintained a Buy rating on Novartis AG (NOVN – Research Report) on March 17 and set a price target of ...

In a report released on March 14, Kerry Holford from Berenberg Bank maintained a Hold rating on Novartis AG (NOVN – Research Report), with a ...

Independent Advisor Alliance raised its holdings in Novartis AG (NYSE:NVS – Free Report) by 23.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC.

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...

Alnylam Pharmaceuticals, Inc.’s ALNY share price has surged by 11.75%, which has investors questioning if this is right time ...

February 25, 2025 Sandoz family foundation offers $3 billion worth of Novartis shares Emasan AG, an arm of the Sandoz Family Foundation, has launched a public offering of some 26.5 million shares ...

As of 10:08:11 AM EDT. Market Open. On Wednesday, Novartis AG (NYSE:NVS) announced safety and efficacy results from the Phase 3 program for investigational intrathecal onasemnogene abeparvovec ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Let's say you have $1,000 to invest right now. The Vanguard International Dividend Appreciation ETF ( VIGI -0.19%) is a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In CQV Co. Ltd. v. Merck Patent GmbH, the Federal Circuit addressed (1) the interaction of indemnification agreements with Article III standing ...